Spur Therapeutics logo

Spur Therapeutics

Toward the next generation of gene therapy.

122 employees · est. 2015 · Stevenage, United Kingdom

VS
Orchard Therapeutics - U.S. logo

Orchard Therapeutics - U.S.

Dedicated to transforming the lives of patients with severe and other genetic diseases through innovative gene therapy.

239 employees · est. 2015 · London, United Kingdom

Orchard Therapeutics - U.S. is the larger of the two.

Side-by-Side Comparison

Spur Therapeutics Orchard Therapeutics - U.S.
Founded
2015 2015
Headquarters
Stevenage, United Kingdom London, United Kingdom
Employees
122 239 larger
Industry
Biopharma, Biotechnology, Health Care Biotechnology, Health Care
Funding Stage
Post Ipo Equity Post Ipo Equity
Total Funding
$260.50M $485.00M
Funding Rounds
7 6
Services
Not tracked yet Development of HSC Gene Therapy, Research and Application of Gene Therapy in Genetic Diseases, Patient-centric Therapeutic Solutions
Target Customers
Not tracked yet Families with Members Affected by Genetic Diseases, Healthcare Professionals, Medical Institutions, Researchers in Medical and Genetic Fields
Taxonomy
Gene Therapy, Liver-directed, Inherited Diseases, Clinical Trials, AAV-based Therapy, Hemophilia B, Fabry Disease, Gaucher Disease, Haemophilia A, Innovation, Global Locations, Systemic Diseases, United Kingdom, United States Gene Therapy, Hematopoietic Stem Cell Therapy, Autologous Ex Vivo Therapy, Rare Genetic Diseases, Severe Diseases, Strimvelis, Metachromatic Leukodystrophy, Wiskott-Aldrich Syndrome, Adenosine Deaminase Severe Combined Immunodeficiency, X-linked Chronic Granulomatous Disease, Beta-thalassemia, Clinical Research, Commercial-stage Biotech, Partnerships With Academic Institutions, Curative Treatments
Website
spurtherapeutics.com orchard-tx.com
Spur Therapeutics logo

About Spur Therapeutics

Freeline is a biopharmaceutical company focused on developing liver-directed gene therapies for inherited systemic diseases. With clinical programs for Hemophilia B and Fabry disease, and preclinical programs in Gaucher disease and haemophilia A, the company aims to revolutionize treatment options f...

Orchard Therapeutics - U.S. logo

About Orchard Therapeutics - U.S.

Orchard Therapeutics - U.S., established in 2015, stands as a pioneering force in the Biotechnology and Health Care sectors. As a subsidiary of Kyowa Kirin, it is devoted to transforming lives through innovative gene therapy, particularly targeting severe genetic diseases. Their approach involves th...

We will tell you when either one moves

BounceWatch watches Spur Therapeutics and Orchard Therapeutics - U.S. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Spur Therapeutics and Orchard Therapeutics -... — by email.

Frequently Asked Questions

Spur Therapeutics — Toward the next generation of gene therapy.. Orchard Therapeutics - U.S. — Dedicated to transforming the lives of patients with severe and other genetic diseases through innovative gene therapy.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Spur Therapeutics has raised $260.50M while Orchard Therapeutics - U.S. has raised $485.00M.
Spur Therapeutics and Orchard Therapeutics - U.S. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Spur Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Spur Therapeutics on 11 Sep 2024, and Orchard Therapeutics - U.S. on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy